Leukemia News

Patients with acute leukemia or myelodysplastic syndrome in an active state experienced significantly greater COVID-19 severity but not higher mortality due to the virus, according to research presented at ASH Annual Meeting and Exposition.

Gilteritinib plus azacitidine conferred significantly higher complete remission rates, but similar OS, vs. azacitidine among patients with newly diagnosed, FLT3-mutated acute myeloid leukemia ineligible for intensive induction chemotherapy.

Time-limited venetoclax-based combination therapies conferred superior rates of undetectable minimal residual disease compared with chemoimmunotherapy among fit patients with chronic lymphocytic leukemia, study results showed.

Most patients with chronic lymphocytic leukemia who received ibrutinib plus fludarabine, cyclophosphamide and rituximab continued to maintain deep responses after longer-term follow-up, results of a single arm, phase 2 trial showed.

Younger Black patients with acute myeloid leukemia had worse outcomes than their white counterparts, including a higher early death rate, numerically lower complete remission rate and shorter OS, according to study results.

Treatment with venetoclax plus azacitidine conferred better outcomes than azacitidine alone among select patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Older age, male sex, pre-COVID-19 prognosis of less than 6 months and deferral of ICU care appeared associated with greater risk for mortality among patients with blood cancer and COVID-19, study results showed.

A vast majority of patients with acute myeloid leukemia and myelodysplastic syndrome converted to seropositivity after two COVID-19 vaccine doses, according to a study presented at ASH Annual Meeting and Exposition.

The addition of ivosidenib to azacitidine improved outcomes for certain patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Considerable survival gaps exist among young white, Black and Hispanic individuals with acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.